Dar Bioscience Inc (DARE) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Dar Bioscience Inc   (NASDAQ: DARE)

Select the Financial Report: Select the Period:


Description of Dar Bioscience Inc's Business Segments


Dare Bioscience Inc. Overview

Dare Bioscience Inc. is a biopharmaceutical company committed to the development and commercialization of innovative products specifically for womens health. The company operates across various segments targeting significant unmet medical needs, with a focus on reproductive health and oncology. Its product offerings span a range of therapeutic areas, highlighting an unwavering dedication to improving women’s health outcomes.

Segments

1. Reproductive Health
- This segment serves as Dare Bioscience’s core focus, addressing critical health issues faced by women, particularly those pertinent to the reproductive system. Products in this segment aim to meet the demands for better treatment alternatives in areas such as bacterial vaginosis, menstrual irregularities, and infertility issues.
- Key Product: DARE-BV1, a gel-based therapy for bacterial vaginosis, exemplifies the innovation in this segment, alongside various emerging products aimed at menstrual cycle regulation and fertility enhancement.

2. Oncology
- The oncology segment concentrates on developing specialized products that address cancer conditions predominantly affecting women, such as breast and ovarian cancer. Through this segment, Dare Bioscience aims to contribute to the advancement of treatments that can significantly improve survival rates and quality of life for female cancer patients.

Products

1. DARE-BV1
- Overview: A microbiome-based, bioadhesive gel specifically formulated to treat bacterial vaginosis.
- Development Stage: Currently in late-stage clinical trials, DARE-BV1 has shown promising efficacy in clinical studies, positioning it as a potential first-line treatment option for this common gynecological condition.

2. DARE-HRT1
- Overview: Developed to cater to unmet needs in hormone replacement therapy, this product aims to alleviate menopausal symptoms such as hot flashes and mood swings.
- Development Stage: Currently in preclinical development, DARE-HRT1 seeks to provide effective symptom relief without systemic side effects typically associated with conventional hormone therapies.

3. DARE-FRT1
- Overview: Aimed at regulating fertility, this product is designed to enhance reproductive wellness among women and address hormonal fluctuations during the menopausal transition.
- Unique Benefit: It aims not only to stabilize hormonal balance but also to improve related symptoms, such as mood and libido, thereby enhancing overall wellbeing.

4. DARE-SA1
- Overview: Focused on treating vulvar and vaginal atrophy, this product is designed to provide relief from vaginal dryness and discomfort during sexual intercourse, which are common issues faced by menopausal women.
- Expected Outcome: By improving vaginal lubrication and reducing discomfort, DARE-SA1 aims to help restore quality of life and intimacy for women experiencing menopausal symptoms.

Services

1. Clinical Research and Development
- Dare Bioscience engages in rigorous clinical trials to assess the safety and efficacy of its products, demonstrating a commitment to scientific excellence and regulatory compliance in product development.
- A robust pipeline reflects the company’s focus on innovative solutions tailored to womens health needs.

2. Manufacturing
- The company partners with experienced contract manufacturers to ensure the production of high-quality, compliant products that meet stringent industry standards, reinforcing its pledge to quality.

3. Regulatory Affairs
- Dare Bioscience is dedicated to navigating the complex regulatory landscape to ensure all products meet necessary safety standards and regulatory requirements. The company collaborates closely with regulatory agencies to facilitate smooth approval processes for its products.

4. Marketing and Sales
- Utilizing a multichannel marketing approach, Dare Bioscience promotes its products through direct-to-consumer advertising networks and strategic partnerships with healthcare professionals and medical institutions.
- This comprehensive strategy ensures that products reach the women who need them most, bridging gaps in awareness and access in womens health.

In summary, Dare Bioscience Inc. strives to make impactful contributions to women’s health through its dedicated segments, innovative products, and robust services, focusing on addressing significant health challenges faced by women today.


Composition of Dar Bioscience Inc Revenues by Segments

 
Reportable Research and development services and royalty revenue    180.85 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Reportable Research and development services and royalty revenue 0.34 180.85 %
Total 0.19 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Reportable Research and development services and royalty revenue - 123.02 %
Total - 23.32 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Reportable Research and development services and royalty revenue -5.97 -
Total -2.98 -




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Reportable Research and development services and royalty revenue - -
Total - -




Annual Report on Dar Bioscience Inc Divisions, Sales by Country

 
Reportable Segment   Reportable Segment Segment contribution to total sales 100 % of total Revenue
License fee revenue and other revenue   License fee revenue and other revenue Segment contribution to total sales 100 % of total Revenue
Reportable License fee revenue and other revenue   Reportable License fee revenue and other revenue Segment contribution to total sales 100 % of total Revenue


Twelve months ended 2025
DARE s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Total 1.03 100 %
Reportable Segment 1.03 100 %
License fee revenue and other revenue 1.03 100 %
Reportable License fee revenue and other revenue 1.03 100 %


Twelve months ended 2025
DARE s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -13.40 -
Reportable Segment -13.55 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Total 10429.36 % -
Reportable Segment 10429.36 % -
Reportable Royalty revenue - -
License fee revenue and other revenue 10429.36 % -
Reportable License fee revenue and other revenue 10429.36 % -
Royalty revenue - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.